Number 812 • September 2019

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Apotex Inc. and Sandoz Canada Inc. that the shortages for Apo-Feno-Super 160 mg Tablet (DIN 02246860) and Sandoz Fenofibrate S 160 mg Tablet (DIN 02288052) respectively, have been resolved. Due to the long-term nature of these shortages, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **September 30, 2019**.

FENOFIBRATE

160 MG TABLET

00002246860	APO-FENO-SUPER	APX	\$ 0.2723
00002288052	SANDOZ FENOFIBRATE S	SDZ	\$ 0.2723
00002241602	LIPIDIL SUPRA	BGP	\$ 1.3362

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Quinapril 5 mg Tablet (DIN 02248499) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 14, 2019**.

QUINAPRIL

5 MG TABLET

00002248499	APO-QUINAPRIL	APX	\$ 0.2321
00001947664	ACCUPRIL	PFI	\$ 0.9742

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Quinapril 10 mg Tablet (DIN 02248500) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 14, 2019**.

QUINAPRIL

10 MG TABLET

00002248500	APO-QUINAPRIL	APX	\$ 0.2321
00001947672	ACCUPRIL	PFI	\$ 0.9742

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Quinapril 40 mg Tablet (DIN 02248502) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 14, 2019**.

QUINAPRIL

40 MG TABLET

00002248502	APO-QUINAPRIL	APX	\$ 0.2321
00001947699	ACCUPRIL	PFI	\$ 0.9742

Alberta Blue Cross has been advised by Actavis Pharma Company that the shortage for Act Dextroamphetamine SR 15 mg Sustained-Release Capsule (DIN 02448327) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 16, 2019**.

DEXTROAMPHETAMINE SULFATE

15 MG SUSTAINED-RELEASE CAPSULE

00002448327	ACT DEXTROAMPHETAMINE SR	APH	\$ 0.9898
00001924567	DEXEDRINE	PAL	\$ 1.1131

Product supply shortage addressed for Alberta Human Services Drug Benefit Supplement (HSDBS)

Alberta Blue Cross has been advised by Pendopharm Inc. that the shortage for Cromolyn 2% Ophthalmic Solution (DIN 02009277) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **October 17, 2019**.

SODIUM CROMOGLYCATE

2% OPHTHALMIC SOLUTION

00002009277	CROMOLYN	PPH	\$ 0.9500
00002230621	OPTICROM	ALL	\$ 1.0130

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit** ab.bluecross.ca/providers/pharmacy-home.php



